LYON, France, September 25, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announces today that oral presentations of the latest results obtained on AdoShell® Islets, an immunoprotective hydrogel containing islets of Langerhans for the treatment of diabetes by cell therapy, will be given at two int
Related Keywords
United States ,Paris ,France General ,France ,Hamburg ,Germany ,San Diego ,California ,Courbebaisse ,Aquitaine ,Pierre Louis Germain ,Olivier Soula ,Islet Transplant Association ,International Xenotransplantation Association ,European Association For The Study Of Diabetes ,International Pancreas ,Regenerative Medicine Society ,Euronext ,European Medicines Agency ,Regulatory News ,Euronext Paris ,Annual Meeting ,European Association ,Paris Hall ,Cell Transplant ,French Autorit ,Relations Presse ,Treasd ,Islet Transplantation ,Islets Of Langerhans ,Research And Development ,Iopharmaceutical Company ,Oral Presentations ,A Geissler ,Immunosuppression ,Diabetes Treatment ,Diabetes ,Ma ,
comparemela.com © 2020. All Rights Reserved.